

Genome-wide analysis of DNA methylation array and microarray in human oral epithelial cells stimulated by arecoline for prolong period - Involvement of aberrant expression of DUSP4 gene in betel quid chewing related oral cancer

著者	Bhoj Raj Adhikari
学位名	博士（歯学）
学位授与機関	北海道医療大学
学位授与年度	平成30年度
学位授与番号	30110甲第306号
URL	http://id.nii.ac.jp/1145/00064676/

**Genome-wide analysis of DNA methylation array
and microarray in human oral epithelial cells
stimulated by arecoline for prolong period
-Involvement of aberrant expression of DUSP4 gene in betel
quid chewing-related oral cancer-**

平成 31 年度
北海道医療大学大学院歯学研究科

ADHIKARI Bhoj Raj

**Genome-wide analysis of DNA methylation array
and microarray in human oral epithelial cells
stimulated by arecoline for prolonged period
-Involvement of aberrant expression of DUSP4 gene in betel
quid chewing-related oral cancer-**

January 2019
Graduate School of Dentistry,
Health Sciences University of Hokkaido

ADHIKARI Bhoj Raj

Abstract

1. Introduction

Oral cancer is the eighth most common cancer in humans. Both environmental and genetic factors induce the development of oral cancer. Although several studies have demonstrated the factors involved in betel quid chewing-related oral cancer, the mechanism by which this cancer is caused remains elusive. Genetic mutations and aberrant DNA methylations have been suggested to be involved in the development of oral cancer. Unlike genetic mutations, DNA hypermethylations are reversible and can be used as diagnostic and therapeutic targets. The objective of this study was to detect novel DNA hypermethylations that can be applied to diagnostic, predictive, interceptive, and therapeutic approaches for betel quid chewing-related oral cancer.

2. Materials and methods

a. Genome-wide analysis

Human gingival epithelial progenitors (HGEPs) were cultured and treated with a 3-day alternating regimen with/without arecoline (50 $\mu\text{g/ml}$) for 1 month. Untreated samples were used as controls. DNA microarrays were used for genomic DNA analysis (methylation array) and global analysis of mRNA expression levels (microarray) in the samples.

b. Reproducibility of the methylation array and microarray data

For the reproducibility of the methylation array and microarray data, the DNA samples were treated with sodium bisulfite and quantitative methylation-specific polymerase chain reaction (qMSP) was performed; mRNA expression was analyzed by quantitative reverse transcription polymerase chain reaction (qRT-PCR).

c. Analysis of dual-specificity phosphatase 4 (DUSP4) gene in oral cancer cell line

To examine the expression of DUSP4 gene in oral cancer, four cancer cell lines HSC4, SAS, BSC-OF, and HSY were cultured and treated with an alternating regimen of arecoline (50 $\mu\text{g/ml}$) for 3 days each for a total of 7 days.

d. Signaling pathway analysis

29 To examine the presence of any other mechanism, in addition to hypermethylation, the levels
30 of phosphorylated c-Jun N-terminal kinase (pJNK) in the HGEPs treated with or without
31 arecoline were determined using cell based enzyme-linked immunosorbent assay (ELISA).

32 e. Histological and immunohistochemical evaluations, and CpG methylation analysis

33 Twenty oral tissue samples from cancer patients with betel quid chewing habit were
34 obtained from Sri Lanka, and 22 samples (13, oral cancer; 9, fibrous polyp) from betel quid
35 non-chewers were retrieved from the archives of Health Sciences University of Hokkaido
36 (HSUH), Japan. Immunohistochemical examinations of the tissue samples were performed
37 using anti-DUSP4 antibody. DUSP4 immunoreactivity was assessed in the nuclei of the
38 epithelial cells. Genomic DNA was extracted from the tissue samples, which were then
39 treated with sodium bisulfite and subjected to qMSP.

40 f. Statistical analysis

41 The results were analyzed using Mann-Whitney U test with p-value <0.05 accepted as
42 statistically significant.

43

44 3. Results

45 CpG island methylation array and global analysis of mRNA revealed 8638 and 455 genes
46 with more than 2-fold increase in methylation and downregulation of mRNA expression
47 respectively, in HGEP samples stimulated with arecoline for a period of 1 month. Among
48 them, 21 were tumor suppressor genes within -1000bp in the promoter region. Four candidate
49 genes (HNRNPH3, BCL2L11, TFAP2A, and DUSP4) with the highest amounts of
50 hypermethylation in their promoter regions and downregulated levels of mRNA expression
51 were selected. Significant hypermethylation and downregulation in the expression levels of
52 the *DUSP4* gene were noted in the HGEPs treated with arecoline for a period of 7 days and 1
53 month. Methylation levels of *DUSP4* were significantly higher in all four cancer cell lines
54 without arecoline treatment when compared to the HGEPs. The mRNA expression level of
55 *DUSP4* in the untreated BSC-OF cell line was not significantly different from that in the
56 HGEPs; however, the levels were downregulated after arecoline treatment. pJNK levels were

57 also elevated in samples treated with arecoline for a period of 1 month.

58 Immunohistochemical (IHC) staining revealed significantly higher expression levels of
59 DUSP4 in betel quid chewers (66.85 ± 3.0) when compared to the non-chewing oral cancer
60 patients (20.34 ± 4.7). CpG islands in DUSP4 were significantly hypermethylated in samples
61 obtained from betel quid chewers (89.8 ± 2.6) when compared to those from the non-chewing
62 oral cancer patients (44.7 ± 10.6) and healthy controls (49.4 ± 13.1).

63

64 4. Conclusion

65 In the present study, genome-wide DNA hypermethylation and global mRNA microarray
66 analysis were carried out using CpG island DNA methylation array and DNA microarray in
67 HGEPs stimulated with arecoline. To the best of our knowledge, this is the first report to
68 demonstrate hypermethylation of DUSP4 followed by the downregulation of its mRNA
69 expression levels in betel quid-related oral cancer. Our findings indicate that DUSP4
70 hypermethylation can be applied as a target for diagnostic, predictive, interceptive, and
71 therapeutic approaches in these cancers.